

Date: 27th April, 2015

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia:

1. Approved the Audited Financial Results for the year ended 31st March, 2015.
2. Recommended a dividend of Rs. 3.50 (175%) per Equity Share of face value of Rs. 2 each, subject to approval of Shareholders at the ensuing Annual General Meeting.
3. Appointed Mr. Pranav Amin as Joint Managing Director w.e.f. 27th April, 2015.
4. Appointed Mr. Shaunak Amin as Joint Managing Director w.e.f. 27th April, 2015.

Further, we enclose herewith the following for the financial year ended on 31st March, 2015:

1. Consolidated Audited Financial Results.
2. Standalone Audited Financial Results.
3. Press Release dated 27th April, 2015.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For **Alembic Pharmaceuticals Limited**

A. K. Desai

Ajay Kumar Desai
Vice-President-Finance &
Company Secretary

Encl.: A/a

CIN:
L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

**AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31ST MARCH, 2015**

Rs. In Lacs

	Particulars	CONSOLIDATED				
		Quarter Ended			Year Ended	
		March-15	December-14	March-14	March-15	March-14
		(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
PART- I						
1	(a) Net Sales / Income from Operations					
	Domestic	27,530	29,281	24,536	1,17,394	1,04,106
	Exports	23,265	22,209	21,986	89,379	82,735
	Total	50,795	51,490	46,522	2,06,773	1,86,841
	Less : Excise Duty	612	395	189	1,505	771
	Net Sales / Income from Operations	50,183	51,095	46,333	2,05,268	1,86,070
	(b) Other Operating Income	115	83	70	344	251
	Total Income from Operations	50,298	51,178	46,403	2,05,612	1,86,321
2	Expenses					
	(a) Decrease/(Increase) in stock in trade and work in progress	447	(1,399)	407	(7,289)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	11,459	12,361	13,088	54,049	55,593
	(c) Purchase of traded goods	5,449	6,471	4,128	24,692	19,807
	(d) Employees' Cost	7,522	7,916	6,715	30,676	24,700
	(e) Marketing Expense	3,945	5,615	3,088	21,766	16,618
	(f) Research and Development Expense	3,049	3,051	3,120	12,162	11,643
	(g) Excise Duty	95	427	62	796	425
	(h) Other Expenditure	8,466	6,488	6,666	28,153	25,829
	Total Expenses	40,432	40,930	37,274	1,65,005	1,50,550
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,866	10,248	9,129	40,607	35,771
4	Other Income	185	13	277	230	319
5	Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,051	10,261	9,406	40,837	36,090
6	Depreciation	1,096	1,190	1,099	4,441	4,049
7	Interest (Net)	36	(18)	229	178	981
8	CSR Expense	71	91	-	310	-
9	Net Profit from Ordinary Activities before Tax	8,848	8,998	8,078	35,908	31,060
10	Tax Expense					
	Less : Provision for Current Tax	1,831	1,933	1,801	7,635	6,847
	Add : MAT Credit Entitlement	739	-	-	739	-
	Less : Provision for Deferred Tax Liability	739	-	148	739	663
11	Net Profit from Ordinary Activities after Tax	7,017	7,065	6,129	28,273	23,550
12	Share of Profit of Associates	16	1	-	20	-
13	Net Profit after Tax and share of profit of associates	7,033	7,066	6,129	28,293	23,550
14	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770	3,770
15	Reserves excluding Revaluation Reserve	-	-	-	84,694	63,787
16	Basic & Diluted EPS (Not Annualised)	3.73	3.75	3.25	15.01	12.49
PART- II						
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 31st MARCH, 2015				
	Pending at the beginning of the quarter				NIL	
	Received during the quarter				NIL	
	Disposed of during the quarter				NIL	
	Remaining unresolved at the end of the quarter				NIL	



Alembic Pharmaceuticals Limited

Consolidated Statement of Assets and Liabilities

Rs. In Lacs

Particulars		As at 31st March, 2015 (Audited)	As at 31st March, 2014 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	3,770	3,770
	(b) Reserves and surplus	84,694	63,787
	Sub-total - Shareholders' funds	88,464	67,557
2	Non-current liabilities		
	(a) Long-term borrowings	1,880	5,222
	(b) Deferred tax liabilities (net)	3,143	2,272
	(c) Other long-term liabilities	1,284	1,270
	(d) Long-term provisions	936	668
	Sub-total - Non-current liabilities	7,244	9,432
3	Current liabilities		
	(a) Short-term borrowings	21,970	2,542
	(b) Trade payables	31,088	28,844
	(c) Other current liabilities	5,863	6,062
	(d) Short-term provisions	9,488	7,288
	Sub-total - Current liabilities	68,409	44,737
	TOTAL - EQUITY AND LIABILITIES	1,64,117	1,21,726
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	59,473	41,763
	(b) Goodwill	3,528	-
	(c) Non-current investments	226	336
	(d) Long-term loans and advances	11,815	9,482
	Sub-total - Non-current assets	75,043	51,581
2	Current assets		
	(a) Inventories	38,277	31,078
	(b) Trade receivables	36,117	27,337
	(c) Cash and Bank Balance	2,683	2,396
	(d) Short-term loans and advances	11,998	9,334
	Sub-total - Current assets	89,074	70,145
	TOTAL - ASSETS	1,64,117	1,21,726

Place : Vadodara
Date : 27th April, 2015



For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and Managing Director

**AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31ST MARCH, 2015**

Rs. in lacs

	Particulars	STANDALONE				
		Quarter Ended			Year Ended	
		March-15	December-14	March-14	March-15	March-14
		(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
PART- I						
1	(a) Net Sales / Income from Operations					
	Domestic	27,530	29,281	24,536	1,17,394	1,04,106
	Exports	22,361	21,233	21,092	85,681	80,793
	Total	49,891	50,514	45,628	2,03,075	1,84,899
	Less : Excise Duty	612	395	189	1,505	771
	Net Sales / Income from Operations	49,279	50,119	45,439	2,01,570	1,84,128
	(b) Other Operating Income	101	83	70	330	251
	Total Income from Operations	49,380	50,202	45,509	2,01,900	1,84,379
2	Expenses					
	(a) Decrease/(Increase) in stock in trade and work in progress	447	(1,399)	407	(7,289)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	11,459	12,361	13,088	54,049	55,593
	(c) Purchase of traded goods	5,495	6,395	4,128	24,663	19,807
	(d) Employees' Cost	7,245	7,658	6,677	29,657	24,446
	(e) Marketing Expense	3,633	5,272	2,934	20,318	16,075
	(f) Research and Development Expense	2,820	2,559	2,593	10,903	10,510
	(g) Excise Duty	95	427	62	796	425
	(h) Other Expenditure	8,474	6,371	6,955	27,712	25,686
	Total Expenses	39,668	39,644	36,844	1,60,809	1,48,477
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,712	10,558	8,665	41,091	35,902
4	Other Income	12	13	277	57	319
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	9,724	10,571	8,942	41,148	36,221
6	Depreciation	1,096	1,190	1,099	4,441	4,049
7	Interest (Net)	5	(42)	229	111	981
8	CSR Expense	71	91	-	310	-
9	Net Profit from Ordinary Activities before Tax	8,552	9,332	7,614	36,286	31,191
10	Tax Expense					
	Less : Provision for Current Tax	1,843	1,933	1,752	7,625	6,700
	Add : MAT Credit Entitlement	739	-	-	739	-
	Less : Provision for Deferred Tax Liability	739	-	148	739	663
11	Net Profit from Ordinary Activities after Tax	6,709	7,399	5,714	28,661	23,828
12	Paid up Equity Share Capital	3,770	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	79,586	59,199
14	Basic & Diluted EPS (Not Annualised)	3.56	3.92	3.03	15.20	12.64
PART- II						
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered	139738620	139738620	139738620	139738620	139738620
	- Number of Shares	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	74.13	74.13	74.13	74.13	74.13
	- Percentage of Shares (as a % of the total share capital of the Company)					
B	INVESTOR COMPLAINTS	Quarter Ended on 31st March, 2015				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	NIL				
	Disposed of during the quarter	NIL				
	Remaining unresolved at the end of the quarter	NIL				



Alembic Pharmaceuticals Limited

Statement of Assets and Liabilities - Standalone

		Rs. In Lacs	
Particulars		As at 31st March, 2015 (Audited)	As at 31st March, 2014 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	3,770	3,770
	(b) Reserves and surplus	79,586	59,199
	Sub-total - Shareholders' funds	83,357	62,970
2	Non-current liabilities		
	(a) Long-term borrowings	1,880	5,222
	(b) Deferred tax liabilities (net)	3,143	2,272
	(c) Other long-term liabilities	1,284	1,270
	(d) Long-term provisions	936	668
	Sub-total - Non-current liabilities	7,244	9,432
3	Current liabilities		
	(a) Short-term borrowings	14,981	2,542
	(b) Trade payables	30,238	28,190
	(c) Other current liabilities	5,836	6,062
	(d) Short-term provisions	9,460	7,048
	Sub-total - Current liabilities	60,515	43,843
	TOTAL - EQUITY AND LIABILITIES	1,51,116	1,16,245
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	57,182	41,763
	(b) Non-current investments	3,333	3,333
	(c) Long-term loans and advances	6,503	4,164
	Sub-total - Non-current assets	67,018	49,260
2	Current assets		
	(a) Inventories	38,248	31,078
	(b) Trade receivables	33,794	26,056
	(c) Cash and Bank Balance	440	534
	(d) Short-term loans and advances	11,615	9,317
	Sub-total - Current assets	84,098	66,985
	TOTAL - ASSETS	1,51,116	1,16,245

Place : Vadodara
Date : 27th April, 2015



For Alembic Pharmaceuticals Limited

(Signature)
Chirayu Amin
Chairman and Managing Director

Notes :

1 The above results, have been duly audited by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.

2 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.

The key information on the standalone financial results are as under:

Particulars	Quarter Ended			Year Ended	
	Mar-15	Dec-14	Mar-14	Mar-15	Mar-14
	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
Net Sales / Income from Operations	49,380	50,202	45,509	2,01,900	1,84,379
Profit Before Tax	8,552	9,332	7,614	36,286	31,191
Profit After Tax	6,709	7,399	5,714	28,661	23,828

3 The Board has recommended dividend of Equity Shares at Rs 3.50 per share i.e 175% for the year ended on 31.03.2015 (P Y Rs. 3.00 per share)

4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

5 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 27th April, 2015



For Alembic Pharmaceuticals Limited

Chirayu Amin

Chairman and Managing Director

Visit us at www.alembic-india.com

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for Quarter/Year ended
31.03.2015

Editor's Synopsis

A) Quarter ended 31st March 2015

- **Successfully passed US FDA audit of formulation facility at Panelav without any 483 observations**
- **Successfully passed US FDA audit of Bio equivalence center without any 483 observations**
- **Net sales up by 9% to Rs 508.0 crores against Rs 465.2 crores**
- **Profit before tax up by 10% to Rs 88.5 crores against Rs 80.8 crores**
- **Net profit after tax up by 15% to Rs 70.3 crores against Rs 61.3 crores**

B) Year ended 31st March 2015

- **Net sales up by 11% to Rs 2067.7 crores against Rs 1868.4 crores**
- **Profit before tax up by 16% to Rs 359.1 crores against Rs 310.6 crores**
- **Net profit after tax up by 20% to Rs 282.9 crores against Rs 235.5 crores**
- **EBITDA margins at 19.6% at Rs 406.1 crores compared to 19.1% at Rs 357.7 crores**

C) Appointment of Mr. Pranav Amin and Mr. Shaunak Amin as Joint Managing Directors of the Company

Vadodara, 27th April, 2015

Alembic Pharmaceuticals Limited reported a 9% increase in revenues to Rs 508.0 crores for the quarter ended 31st March 2015, compared to Rs 465.2 crores in the corresponding quarter last year.

The Company posted 10% growth in profit before tax at Rs 88.5 crores for the quarter ended 31st March 2015 against Rs 80.8 crores posted in the corresponding quarter last year.

The net profit grew by 15% at Rs 70.3 crores for the quarter ended 31st March 2015 against Rs 61.3 crores in the corresponding quarter last year.

The company reported 11% increase in revenue for year ended 31st March 2015 to Rs 2067.7 crores against Rs 1868.4 crores in the last year.

The Company reported 16% growth in profit before tax at Rs. 359.1 crores for Year ended 31st March 2015 against Rs. 310.6 crores in the last year. The company also reported 20% growth in net profit for year ended 31st March 2015 Rs 282.9 crores against Rs 235.5 crores in the last year.

Mr. Pranav Amin and Mr. Shaunak Amin were earlier designated as Director & President – International Business and Director & President – Branded Formulations Business respectively. The Company has made significant growth under their leadership and considering their roles and responsibilities, are being re-designated as Joint Managing Directors of the Company with effect from 27th April 2015.

Dividend

The Board has recommended dividend on equity shares at Rs 3.50 per share i.e. 175% for 14-15 (P.Y. Rs 3.00 per share i.e. 150%)

India Branded Formulations Business

The India Branded formulations business grew by 16% to Rs 232.1 crores in the quarter against Rs 199.4 crores over the corresponding quarter of the previous year.

The India Branded formulations business posted sales for year ended 31st March 2015 of Rs 980.8 crores against Rs 850.6 crores with 15% growth over the previous year.

Specialty and Acute segments grew by 22% and 11% respectively in current quarter. For the year the growth are 21% and 9% respectively for Specialty and Acute segments.

International Generics

International Generic Formulation grew by 8% to Rs 147.9 crores in the quarter against Rs 136.6 crores over the corresponding quarter of the previous year.

International Generic Formulation posted sales for the year ended 31st March 2015 of Rs 518.5 crores against Rs 468.4 crores with 11% growth over the previous year.

2 ANDA applications were filed during the quarter, 7 ANDA applications for the year ended 31st March 2015, taking cumulative ANDA/NDA filings of the Company to 68. During the quarter 1 ANDA approval was received, 5 ANDA approvals for the year ended 31st March 2015, taking cumulative ANDA/NDA approvals to 37 (including 4 tentative approvals).

2 DMF applications were filed during the quarter, 6 DMF applications for the year ended 31st March 2015, taking cumulative DMF filings of the Company to 72.

Summary of Total Revenue is as under:

(Rs in Lacs)						
Particulars	Q4 FY15	Q4 FY14	% Change	FY 14-15	FY 13-14	% Change
Formulation						
India Branded	23208	19945	16%	98084	85064	15%
India Generics	3209	2867	12%	12274	12071	2%
International Branded	903	1759	(-)49%	6349	7360	(-)14%
International Generics	14788	13665	8%	51845	46837	11%
API	8524	8098	5%	36650	33885	8%
Export Incentives	163	188	-	1571	1624	-
Total	50795	46522	9%	206773	186841	11%

The Profit break-up is as under:

(Rs in Lacs)						
Particulars	Q4 FY15	Q4 FY14	% Change	FY 14-15	FY 13-14	% Change
EBITDA	9866	9129	8%	40607	35771	14%
Profit Before Tax	8848	8078	10%	35908	31060	16%
Net Profit after Tax	7033	6129	15%	28293	23550	20%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Email: ajay.desai@alembic.co.in

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in